Efficacy Study & Safety Evaluation of SR-T100 Gel in Actinic Keratosis Treatment
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Studies of SR-T100 gel and its clinical relevance in the treatment of AK, providing adequate
measured outcomes for skin lesion treatment. In addition to the high complete response rate
(90.0%) as compared with the conventional therapy, the most significant result was that no
undesirable side effects were associated with the use of SR-T100 gel. The result also shows
approximately 80% of study subjects had a complete response in phase II clinical trial
conducted in Taiwan; hence, result from our study model suggested SR-T100 gel offers
beneficial therapeutic values in treatment of AK is harmless to the skin as well as high
tolerance level displayed by majority of patients.